What ChondroFiller injection costs

ChondroFiller injection at London Cartilage Clinic is priced on a volume basis, with three tiers depending on how much product the defect requires:

• One box — £3,000
• Two boxes — £5,500
• Three boxes — £8,000

The same rates apply regardless of which joint is being treated — knee, hip, ankle, shoulder, or any other — so the box count alone determines the figure. Most patients are treated with a single box; larger surface areas or multi-compartment defects may require two or three.

These are guide costs confirmed by the clinic, and they are all-inclusive: there are no additional day-of charges on top of the quoted figure. The next section sets out exactly what each tier covers.

ChondroFiller is exclusively self-funded private treatment and is not available on the NHS. Whether private medical insurance contributes depends on individual policy terms and requires written pre-authorisation before the appointment.

What the quoted price includes

Each quoted figure is all-inclusive — no additional procedural fees are billed on the day. The appointment itself runs for 30 to 45 minutes as an outpatient visit under real-time ultrasound guidance, with no general anaesthetic and no surgical admission required. That context matters when comparing cost against day-case or surgical alternatives, where headline figures often cover only the operative element and ancillary costs appear separately.

At every tier, the price covers:

• Pre-injection consultation and imaging review — clinical assessment and review of existing MRI or relevant imaging before any product is administered
• Real-time ultrasound guidance — live imaging throughout the appointment to confirm accurate placement of the scaffold
• The ChondroFiller product itself — the acellular collagen scaffold, imported from Germany under prescription by meidrix biomedicals GmbH, and the single largest cost component within the quoted figure
• IV antibiotic cover on the day — prophylactic antibiotics administered intravenously during the appointment
• Six-week clinical follow-up — a review with the treating clinician six weeks after the injection
• Unlimited nurse support and wound care — post-procedure nursing contact as needed

Because the scaffold product carries the dominant share of the total, box count — rather than any variation in the clinical service around it — is the primary pricing variable. How the treating clinician determines the appropriate box count is covered in the next section.

Why the cost scales with box count

The pricing logic follows directly from how the scaffold works. ChondroFiller functions through acellular matrix-induced chondrogenesis: the collagen scaffold, once placed under ultrasound guidance, recruits the patient's own progenitor cells from the surrounding synovium and subchondral bone to support endogenous repair. The volume of scaffold material therefore correlates with the area requiring coverage — and because the product itself carries the dominant share of each tier's cost, box count rather than any other variable drives the price difference between tiers.

For most patients presenting with a focal, single-compartment defect, one box is sufficient. Two or three boxes are indicated where the surface area is greater, the damage spans more than one compartment, or clinical assessment determines that a larger scaffold volume is needed to achieve adequate coverage of the affected site.

Neither age nor defect size automatically disqualifies a patient from the injection route: there is no upper age limit and no defect-size exclusion, including for patients described as 'bone on bone'.

The required box count is not something patients determine in advance. Following review of MRI imaging and a clinical assessment, the treating clinician establishes the appropriate volume — and with it, the applicable price tier.

Combination therapy pricing

Advanced or end-stage osteoarthritis — Kellgren-Lawrence Grade III or IV — can present a more complex clinical picture than a focal defect alone. Where both the articular surface and the joint environment are compromised, two documented combination tiers address the additional therapeutic demands, each carrying a distinct price that reflects a distinct mechanism.

Dual Combo — £6,000

This tier pairs ChondroFiller (2.3 mL), placed on the bone ends as a regenerative scaffold, with Arthrosamid (6 mL), a polyacrylamide hydrogel delivered into the synovium. The two products work in different tissue layers through different mechanisms and are not interchangeable: ChondroFiller provides the acellular collagen matrix to support endogenous repair at the cartilage surface; Arthrosamid acts as a cushioning barrier within the synovial space. The combination exists because Grade III/IV disease may damage both simultaneously — addressing only one layer leaves the other unmanaged.

Ultimate Tri-Active Therapy — £11,000

For cases described clinically as extreme — where structural shielding, synovial barrier protection, and cellular signalling are all required — autologous mesenchymal stem cells (MSCs), harvested from bone marrow, fat tissue, or ear cartilage, are added to the Dual Combo. The pricing reflects a £6,000 combination base plus a £5,000 MSC premium. The MSC component is not presented as cartilage regrowth; rather, MSCs support the body's own repair processes through cellular signalling, working alongside the scaffold and hydrogel rather than replacing either function.

Staged delivery is standard for combination plans: each component requires separate clinical justification and is administered at a separate appointment. MRI findings alone do not determine suitability — a full clinical assessment is required to establish whether the combined approach is appropriate for a given patient's anatomy and disease stage.

The Lifetime Program for long-term joint preservation

For patients who have completed an initial ChondroFiller course, London Cartilage Clinic offers the Longitudinal Lifetime Program — a structured maintenance pathway built around three recurring components: yearly peptides (supportive bioactive compounds used to promote tissue health between injections), an annual MRI to track joint status, and a ChondroFiller top-up injection every two years. The stated clinical aim is lifetime joint preservation: keeping the patient away from total knee or hip replacement for as long as possible through active monitoring and timely scaffold renewal.

The programme is most relevant to patients who have already completed a standalone or combination ChondroFiller course and want structured ongoing oversight rather than episodic treatment. The yearly MRI provides the objective basis for assessing whether the scaffold has supported repair and for detecting any new changes before they become a surgical indication — a meaningful distinction from the more common approach of waiting for symptoms to worsen before acting.

Pricing follows a recurring structure: an annual maintenance fee covers monitoring and the peptide element, with a separate charge for the bi-annual top-up injection. Specific figures for both components are not publicly listed; patients should confirm current costs directly with the clinic when planning ahead.

Funding, insurance, and confirming your costs

Private medical insurance may contribute to the cost in some cases, though coverage is never guaranteed and varies significantly between policies and insurers. CCSD billing codes W3111 (cartilage regeneration with collagen scaffold) and W8500 appear on the fee schedules of Bupa, Aviva, and WPA, meaning the procedure has a recognised coding pathway — but written pre-authorisation is always required before treatment, and whether a claim is approved depends on the individual policy, the clinical indication, and the insurer's assessment. Patients should contact their provider directly and request written confirmation before booking.

For those funding treatment themselves, benchmarking against other providers is difficult. London Cartilage Clinic was the first clinic in the UK to offer ChondroFiller as an injection pathway, and no comparable publicly listed pricing from other UK providers currently exists. The tiers documented in earlier sections reflect all-inclusive guide costs; the figure that applies to any individual patient depends on the box count the treating clinician determines at assessment — not on a self-selected tier.

To find out which tier applies to your joint, defect, and clinical picture, a consultation with the clinic is the practical starting point. Book yours at londoncartilage.com.